Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Poli

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
International Immunology|March 5, 2005
Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID miceCaterina Lapenta, Massimo Spada, Stefano M Santini, et al.
Journal of Virology|August 5, 2011
Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replicationGiovanna Tosi, Greta Forlani, Vibeke Andresen, et al.
Journal of Virus Eradication|May 15, 2020
Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USAChristina K Psomas, Karl Salzwedel, Mario Stevenson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophagesFrancesca Graziano, Marion Desdouits, Livia Garzetti, et al.
Haematologica|February 8, 2006
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapyNicoletta Burighel, Silvia Ghezzi, Silvia Nozza, et al.
Plos One|August 8, 2013
HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expressionManuela Nebuloni, Lidia Zawada, Angelita Ferri, et al.
Journal of Virus Eradication|April 24, 2018
Highlights from the 8<sup>th</sup> International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USAChristina K Psomas, Alain Lafeuillade, David Margolis, et al.
International Journal of Cancer|November 6, 2003
Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patientsElena Nardini, Francesca Neri, Elisa Vicenzi, et al.
Antiviral Therapy|August 3, 2007
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 diseaseAssia Samri, Ruth Goodall, Catherine Burton, et al.
Blood|January 5, 2002
Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factorChiara Bovolenta, Elisabetta Pilotti, Massimiliano Mauri, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
International Immunology|March 5, 2005
Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID miceCaterina Lapenta, Massimo Spada, Stefano M Santini, et al.
Journal of Virology|August 5, 2011
Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replicationGiovanna Tosi, Greta Forlani, Vibeke Andresen, et al.
Journal of Virus Eradication|May 15, 2020
Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USAChristina K Psomas, Karl Salzwedel, Mario Stevenson, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2015
Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophagesFrancesca Graziano, Marion Desdouits, Livia Garzetti, et al.
Haematologica|February 8, 2006
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapyNicoletta Burighel, Silvia Ghezzi, Silvia Nozza, et al.
Plos One|August 8, 2013
HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expressionManuela Nebuloni, Lidia Zawada, Angelita Ferri, et al.
Journal of Virus Eradication|April 24, 2018
Highlights from the 8<sup>th</sup> International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USAChristina K Psomas, Alain Lafeuillade, David Margolis, et al.
International Journal of Cancer|November 6, 2003
Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patientsElena Nardini, Francesca Neri, Elisa Vicenzi, et al.
Antiviral Therapy|August 3, 2007
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 diseaseAssia Samri, Ruth Goodall, Catherine Burton, et al.
Blood|January 5, 2002
Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factorChiara Bovolenta, Elisabetta Pilotti, Massimiliano Mauri, et al.
Pageof 13